Center for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina , Chapel Hill, North Carolina 27599, United States.
ACS Comb Sci. 2013 Jan 14;15(1):10-9. doi: 10.1021/co300106f. Epub 2012 Dec 5.
We have developed an efficient and robust route to synthesize 4,5,7-trisubstituted pyrrolo[3,2-d]pyrimidines as potent kinase inhibitors. This solution-phase synthesis features a SNAr substitution reaction, cross-coupling reaction, one-pot reduction/reductive amination and N-alkylation reaction. These reactions occur rapidly with high yields and have broad substrate scopes. A variety of groups can be selectively introduced into the N5 and C7 positions of 4,5,7-trisubstituted pyrrolopyrimidines at a late stage of the synthesis, thereby providing a highly efficient approach to explore the structure-activity relationships of pyrrolopyrimidine derivatives. Four synthetic analogs have been profiled against a panel of 48 kinases and a new and selective FLT3 inhibitor 9 is identified.
我们开发了一种高效、稳健的合成 4,5,7-三取代吡咯并[3,2-d]嘧啶的路线,这些化合物是有效的激酶抑制剂。该液相合成方法具有 SNAr 取代反应、交叉偶联反应、一锅还原/还原胺化和 N-烷基化反应。这些反应在温和条件下快速进行,具有高产率和广泛的底物范围。在合成的后期阶段,可以选择性地将各种基团引入 4,5,7-三取代吡咯嘧啶的 N5 和 C7 位置,从而为探索吡咯嘧啶衍生物的构效关系提供了一种高效的方法。对 48 种激酶进行了 4 种合成类似物的分析,并确定了一种新的、选择性的 FLT3 抑制剂 9。